Healthway Cancer Care Hospital is now 75% complete

Dedicated cancer care centre targets Q3 launching.

Now 75% complete, the Healthway Cancer Care Hospital being built in Taguig City, Metro Manila, is on track to opening in the third quarter of the year as the Philippines’ first cancer care specialty centre.

Paolo Borromeo, Ayala Corp. (AC) Health president and CEO, heralded the facility’s full range of equipment and services as a dedicated cancer care centre with a 100-bed capacity.

Borromeo said their mission in establishing the facility, under Healthway Medical Network which was acquired by AC Health, is to lower the cost of cancer care whilst providing more competitive and valuable services.

There are about 100,000 Filipinos diagnosed with cancer and, perhaps, another 100,000 who are undiagnosed because of the prohibitive costs of screening. Now that the National Integrated Cancer Control Act has been passed, Healthway positions itself as a significant part of the campaign to face these challenges.

"Our goal was always to try to provide more affordable cancer care here in the Philippines. Cancer is still a huge financial burden to patients and to families,” Borromeo said.

At the helm of this endeavour is Jimmy Ysmael, president and CEO of Healthway Medical Network—which has an entire portfolio of clinics and hospitals, with Dr. Ramy Roxas, a director of the Philippine College of Surgeons Cancer Commission, as medical director of Healthway Cancer Care Hospital, and Dr. Gary Lorenzo as head of the Medical Advisory Council.

To deliver a full range of services from radiation oncology, to surgery, chemotherapy, and palliative care, Healthway has partnered with Varian, a Siemens Healthineers company and equipment provider, and its subsidiary, Cancer Treatment Services International.

The Healthway Cancer Care Hospital’s contribution to the company’s overall portfolio is a specialty component, where it can harness the strength of AC Health’s whole ecosystem of different healthcare assets, which include screening and detection at its various clinics and hospitals, digital facilitation, and pharmaceutical support.

“For instance, creating cancer screening programs more broadly in their clinics, hospitals, and digital platforms would allow them to screen and refer patients to the cancer hospital as needed,” said Borromeo.

The support of the whole system also allows the soon-to-rise facility to offer easily accessible treatment options for their patients on the pharmaceutical side.

Disclaimer: We corrected Rami Rojas to Ramy Roxas. Apologies for this mistake.

Follow the link for more news on

Ayala Healthcare Holdings

Private Hospitals

Also Read

Global REM sleep behaviour disorder market to reach $438.6m by 2028

SG to launch national strategy for allied health professionals

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit

Top News

Global REM sleep behaviour disorder market to reach $438.6m by 2028

It is driven the increasing integration of AI and ML in RBD detection.

Healthcare

1 hour ago

SG to launch national strategy for allied health professionals

It will also implement a mandatory continuing professional education by 2026.

Healthcare

20 hours ago

Bladder cancer cases to hit 340,000 by 2033

Older adults aged 60 and above make up about 87% of diagnosed cases.Bladder cancer cases in eight major markets, including Japan and China, are projected to grow at an annual rate of 2.24%, rising from 280,0000 cases in 2023 to 340,000 in 2033, according to GlobalData. The US will have the highest number of diagnosed cases at approximately 100,000, whilst France will report the lowest at 20,000 for 2023.Antara Bhattacharya, an associate project manager in GlobalData’s Epidemiology team, noted that men are more affected, comprising about 78% of cases, compared to 22% for women. Older adults aged 60 and above make up nearly 87% of diagnosed cases, with younger adults aged 18 to 59 accounting for about 13%.Roughly 45% of bladder cancer cases were diagnosed in early stages, with severe cases making up only 6%. Furthermore, about 79% of cases were detected at early tumour stages, compared to 4% in more advanced stages. Bhattacharya attributed the high diagnosis rates to the increased use of cystoscopy, an invasive diagnostic procedure. However, even with early-stage diagnosis, relapse and recurrence remain common, affecting approximately 74% of cases.Bladder cancer, the ninth most common type of cancer, poses challenges due to the cost and complexity of timely detection. Bhattacharya emphasised the need for comprehensive research and improved medical strategies to enhance early detection and treatment. Ongoing epidemiological studies focusing on stages of bladder cancer with a high likelihood of recurrence can contribute to better treatment outcomes. Effective treatment of bladder cancer involves a multi-pronged approach, combining medical and surgical care, lifestyle adjustments, continuous support, as well as advanced treatments like immunotherapy, targeted therapy, participation in clinical trials, and consistent follow-up.

Healthcare

23 hours ago

Primary open-angle glaucoma cases to grow to 10 million by 2033